- Home
- HLI vs INCY Comparison
HLI vs INCY Comparison
Compare HLI & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLI
- INCY
- Stock Information
- Founded
- HLI 1972
- INCY 1991
- Country
- HLI United States
- INCY United States
- Employees
- HLI N/A
- INCY N/A
- Industry
- HLI Investment Managers
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- HLI Finance
- INCY Health Care
- Exchange
- HLI Nasdaq
- INCY Nasdaq
- Market Cap
- HLI 12.3B
- INCY 13.4B
- IPO Year
- HLI 2015
- INCY 1993
- Fundamental
- Price
- HLI $172.87
- INCY $68.46
- Analyst Decision
- HLI Buy
- INCY Hold
- Analyst Count
- HLI 7
- INCY 20
- Target Price
- HLI $187.67
- INCY $73.81
- AVG Volume (30 Days)
- HLI 306.3K
- INCY 2.1M
- Earning Date
- HLI 07-29-2025
- INCY 07-29-2025
- Dividend Yield
- HLI 1.39%
- INCY N/A
- EPS Growth
- HLI 41.61
- INCY N/A
- EPS
- HLI 5.82
- INCY 0.10
- Revenue
- HLI $2,389,126,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- HLI $10.96
- INCY $13.29
- Revenue Next Year
- HLI $11.58
- INCY $10.47
- P/E Ratio
- HLI $29.72
- INCY $623.03
- Revenue Growth
- HLI 24.80
- INCY 17.13
- 52 Week Low
- HLI $129.32
- INCY $53.56
- 52 Week High
- HLI $192.10
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- HLI 50.11
- INCY 56.95
- Support Level
- HLI $170.59
- INCY $67.57
- Resistance Level
- HLI $174.78
- INCY $71.29
- Average True Range (ATR)
- HLI 2.57
- INCY 1.98
- MACD
- HLI -0.75
- INCY -0.13
- Stochastic Oscillator
- HLI 31.06
- INCY 61.55
About HLI Houlihan Lokey Inc.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.